DAB₃₈₉IL2 (ONTAK^®) fusion protein therapy of chronic lymphocytic leukaemia

Author： Frankel Arthur E Fleming Donald R Powell Bayard L Gartenhaus Ronald

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.3, Iss.1, 2003-02, pp. : 179-186

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anthrax Fusion Protein Therapy of Cancer

Current Protein and Peptide Science, Vol. 3, Iss. 4, 2002-08 ,pp. : 399-407

Bentham Science Publishers

Access to resources Recommend Favorite

Constitutive Expression of a rhIL-2-HSA Fusion Protein in Pichia pastoris Using Glucose as Carbon Source

By Guan Bo Chen Fengxiang Lei Jianyong Li Yunhua Duan Zuoying Zhu Ruiyu Chen Yun Li Huazhong Jin Jian

Applied Biochemistry and Biotechnology, Vol. 171, Iss. 7, 2013-12 ,pp. : 1792-1804

Humana Press, Inc

Access to resources Recommend Favorite

Rituximab for chronic lymphocytic leukemia

By Robak Tadeusz

Expert Opinion on Biological Therapy, Vol. 12, Iss. 4, 2012-04 ,pp. : 503-515

Informa Healthcare

Access to resources Recommend Favorite

Gene therapy for paediatric leukaemia

By Heslop Helen E Rousseau Raphaël F Bollard Catherine M

Expert Opinion on Biological Therapy, Vol. 1, Iss. 4, 2001-07 ,pp. : 663-674

Informa Healthcare

Access to resources Recommend Favorite

Bacterial Expression of an Immunologically Reactive PCV2 ORF2 Fusion Protein

By Liu Q. Willson P. Attoh-Poku S. Babiuk L.A.

Protein Expression and Purification, Vol. 21, Iss. 1, 2001-02 ,pp. : 115-120

Academic Press

Access to resources Recommend Favorite